肥胖成年人静脉注射 750 毫克左氧氟沙星的药代动力学。
Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.
机构信息
UK Healthcare, University of Kentucky College of Pharmacy, 800 Rose St H-110, Lexington, Kentucky 40536-0293, USA.
出版信息
Antimicrob Agents Chemother. 2011 Jul;55(7):3240-3. doi: 10.1128/AAC.01680-10. Epub 2011 May 16.
Abstract
The physiochemical properties of levofloxacin suggest that it is an agent which may exhibit altered pharmacokinetics in obese individuals. The purpose of this study was to describe the pharmacokinetics of a single 750-mg intravenous dose of levofloxacin in both hospitalized and ambulatory obese individuals. The hypothesis was that a standard dose of levofloxacin in obese individuals would achieve serum concentrations likely to be therapeutic. A single levofloxacin dose of 750 mg was infused over 90 min, and seven serial serum samples were subsequently obtained to evaluate the pharmacokinetics after the first dose. The peak concentrations of levofloxacin were comparable to those seen with normal-weight individuals. However, the area under the concentration-time curve and clearance were quite variable. Accelerated clearance was evident in the ambulatory obese individuals. Further investigation of the effects of obesity on the pharmacokinetics of levofloxacin is necessary to ensure optimal dosing.
摘要
左氧氟沙星的理化性质表明，它可能是一种在肥胖个体中表现出药代动力学改变的药物。本研究的目的是描述住院和门诊肥胖个体单次 750mg 静脉注射左氧氟沙星的药代动力学。假设在肥胖个体中使用标准剂量的左氧氟沙星将达到可能具有治疗作用的血清浓度。单次给予 750mg 左氧氟沙星，90 分钟内输注完毕，随后采集 7 份连续的血清样本，以评估首剂后的药代动力学。左氧氟沙星的峰浓度与正常体重个体相似。然而，浓度-时间曲线下面积和清除率差异很大。门诊肥胖个体中明显存在清除加速。需要进一步研究肥胖对左氧氟沙星药代动力学的影响，以确保最佳剂量。
相似文献
1
Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.肥胖成年人静脉注射 750 毫克左氧氟沙星的药代动力学。
Antimicrob Agents Chemother. 2011 Jul;55(7):3240-3. doi: 10.1128/AAC.01680-10. Epub 2011 May 16.
2
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.750毫克静脉注射左氧氟沙星与不同剂量甲硝唑在健康成年受试者中的药代动力学和药效学。
Antimicrob Agents Chemother. 2004 Dec;48(12):4597-605. doi: 10.1128/AAC.48.12.4597-4605.2004.
3
Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.左氧氟沙星对猫单次静脉注射及多次口服给药后的药代动力学
J Vet Pharmacol Ther. 2005 Aug;28(4):363-9. doi: 10.1111/j.1365-2885.2005.00669.x.
4
Pharmacokinetics of levofloxacin in male camels (Camelus dromedarius).左氧氟沙星在雄性单峰骆驼（骆驼属单峰驼）中的药代动力学
J Vet Pharmacol Ther. 2009 Jun;32(3):296-9. doi: 10.1111/j.1365-2885.2008.01023.x.
5
Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves.左氧氟沙星在杂交犊牛单次肌肉注射后的药代动力学、尿排泄及给药方案
J Vet Sci. 2006 Dec;7(4):333-7. doi: 10.4142/jvs.2006.7.4.333.
6
Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.健康成年人静脉注射左氧氟沙星和阿奇霉素后的稳态血浆及支气管肺浓度。
Antimicrob Agents Chemother. 2003 Aug;47(8):2450-7. doi: 10.1128/AAC.47.8.2450-2457.2003.
7
Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.左氧氟沙星静脉注射和口服给药在医学重症监护病房危重症成年患者中的药代动力学
Pharmacotherapy. 2002 Oct;22(10):1216-25. doi: 10.1592/phco.22.15.1216.33484.
8
Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.左氧氟沙星在重度烧伤患者中的药代动力学和药效学
Antimicrob Agents Chemother. 2006 Jun;50(6):1937-45. doi: 10.1128/AAC.01466-05.
9
Disposition kinetics, urinary excretion and dosage regimen of levofloxacin formulation following single intravenous administration in crossbred calves.左氧氟沙星制剂在杂交犊牛单次静脉给药后的处置动力学、尿排泄及给药方案
Vet Res Commun. 2007 Oct;31(7):873-9. doi: 10.1007/s11259-007-0090-8.
10
Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves.氧氟沙星与对乙酰氨基酚同时给药在杂交犊牛体内的处置动力学及给药方案
J Vet Sci. 2007 Dec;8(4):357-60. doi: 10.4142/jvs.2007.8.4.357.
引用本文的文献
1
Development of a Population Pharmacokinetic Model of Levofloxacin in Healthy Adults and Identification of Optimal Dosing Regimens.健康成年人左氧氟沙星群体药代动力学模型的建立及最佳给药方案的确定。
Pharmaceuticals (Basel). 2025 Apr 25;18(5):621. doi: 10.3390/ph18050621.
2
Clinical Pharmacokinetics of Antitubercular Drugs in the Overweight and Obese Population: Implications for Dosage Adjustments.抗结核药物在超重和肥胖人群中的临床药代动力学：对剂量调整的意义。
Clin Pharmacokinet. 2025 Feb;64(2):193-214. doi: 10.1007/s40262-024-01442-8. Epub 2025 Jan 10.
3
Oral Antibiotics for Bacteremia and Infective Endocarditis: Current Evidence and Future Perspectives.用于治疗菌血症和感染性心内膜炎的口服抗生素：当前证据与未来展望
Microorganisms. 2023 Dec 18;11(12):3004. doi: 10.3390/microorganisms11123004.
4
Individualized antibiotic dosage regimens for patients with augmented renal clearance.针对肾脏清除率增加患者的个体化抗生素给药方案。
Front Pharmacol. 2023 Jul 26;14:1137975. doi: 10.3389/fphar.2023.1137975. eCollection 2023.
5
Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability.泌尿系统感染中氟喹诺酮类药物有效个体化给药的关键因素：个体间药代动力学和药效学变异性
Antibiotics (Basel). 2022 May 11;11(5):641. doi: 10.3390/antibiotics11050641.
6
Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report.一名肥胖青少年左氧氟沙星的治疗药物监测：病例报告
J Pediatr Pharmacol Ther. 2020;25(3):261-265. doi: 10.5863/1551-6776-25.3.261.
7
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.严重病态肥胖患者（体重指数≥40 kg/m²）的左氧氟沙星给药方案应以基于理想体重的肌酐清除率估计值为指导，并通过治疗药物监测进行优化。
Clin Pharmacokinet. 2014 Aug;53(8):753-62. doi: 10.1007/s40262-014-0154-1.
8
Antibiotic prophylaxis in bariatric surgery with continuous infusion of cefazolin: determination of concentration in adipose tissue.在减重手术中持续输注头孢唑林进行抗生素预防：脂肪组织中浓度的测定
Obes Surg. 2014 Sep;24(9):1487-91. doi: 10.1007/s11695-014-1231-0.
9
Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns.左氧氟沙星的个体化治疗：关注药代动力学问题
Ther Clin Risk Manag. 2014 Mar 27;10:217-27. doi: 10.2147/TCRM.S59079. eCollection 2014.
10
Antibiotic therapy of pneumonia in the obese patient: dosing and delivery.肥胖患者肺炎的抗生素治疗：剂量和给药途径。
Curr Opin Infect Dis. 2014 Apr;27(2):165-73. doi: 10.1097/QCO.0000000000000045.
本文引用的文献
1
Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method.
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):165-72. doi: 10.1016/j.jchromb.2003.10.031.
2
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.氟喹诺酮类抗生素的AUIC折点及其与细菌杀灭率的关联。第1部分：体外和动物模型。
Ann Pharmacother. 2003 Sep;37(9):1287-98. doi: 10.1345/aph.1C199.
3
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.静脉注射左氧氟沙星在早发性呼吸机相关性肺炎患者中的药代动力学和药效学
Clin Pharmacokinet. 2003;42(6):589-98. doi: 10.2165/00003088-200342060-00008.
4
Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.左氧氟沙星静脉注射和口服给药在医学重症监护病房危重症成年患者中的药代动力学
Pharmacotherapy. 2002 Oct;22(10):1216-25. doi: 10.1592/phco.22.15.1216.33484.
5
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
Pharmacotherapy. 2001 Oct;21(10 Pt 2):233S-252S. doi: 10.1592/phco.21.16.233s.33992.
6
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.氟喹诺酮类药物对社区获得性呼吸道感染患者肺炎链球菌的药效学
Antimicrob Agents Chemother. 2001 Oct;45(10):2793-7. doi: 10.1128/AAC.45.10.2793-2797.2001.
7
Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.健康志愿者中多次静脉注射750毫克左氧氟沙星的安全性和药代动力学。
Antimicrob Agents Chemother. 2001 Jul;45(7):2122-5. doi: 10.1128/AAC.45.7.2122-2125.2001.
8
Pharmacokinetics of antibiotics in burn patients.烧伤患者抗生素的药代动力学
J Antimicrob Chemother. 1999 Sep;44(3):319-27. doi: 10.1093/jac/44.3.319.
9
Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients.左氧氟沙星高剂量及延长给药间隔方案在人类免疫缺陷病毒感染患者中的药代动力学及安全性
Antimicrob Agents Chemother. 1999 Sep;43(9):2323-7. doi: 10.1128/AAC.43.9.2323.
10
Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group.
Ann Pharmacother. 1998 Dec;32(12):1275-83. doi: 10.1345/aph.18122.
Zotero 插件